PharmEasy-owned Thyrocare Technologies delivered a strong performance in Q4 FY26, reporting a sharp rise in profitability, strong revenue growth, expanding diagnostic volumes, and continued network expansion across India. The healthcare diagnostics company posted a consolidated net profit of ₹48.7 crore in Q4 FY26, marking a 128 percent year-on-year increase from ₹21.3 crore in the corresponding quarter last year. The strong performance highlights growing momentum in India’s healthcare, diagnostics, and technology-driven wellness ecosystem while reinforcing Thyrocare’s position as a leading player in India’s rapidly evolving diagnostics market.
As part of the latest D2C news India and Indian D2C updates, Thyrocare’s growth reflects how healthcare-focused direct-to-consumer India businesses are scaling rapidly through omnichannel healthcare delivery, diagnostics expansion, digital health integration, and growing preventive healthcare awareness among Indian consumers. The company’s strong quarterly results also align with broader D2C market trends 2025, where technology-enabled healthcare and wellness platforms are emerging as one of the fastest-growing segments within the D2C ecosystem India.
Revenue from operations grew 20 percent year-on-year to ₹224 crore during Q4 FY26 compared to ₹187.2 crore in Q4 FY25. Sequentially, revenue also increased nearly 5 percent from ₹213.3 crore, supported by strong operating leverage, rising pathology volumes, and increasing franchise network contribution. EBITDA for the quarter rose 31 percent year-on-year and 8 percent sequentially to ₹75.1 crore, while EBITDA margins improved significantly to 34 percent from 31 percent a year earlier. The performance highlights strong operational efficiency and improving scale economics across Thyrocare’s healthcare operations.
The company processed 5.9 crore tests during Q4 FY26, reflecting a strong 29 percent year-on-year increase. The rise in testing volumes reinforces Thyrocare’s leadership in India’s diagnostics and preventive healthcare industry while highlighting changing D2C consumer behavior India, where consumers are increasingly prioritising preventive healthcare, wellness diagnostics, and technology-enabled medical services.
One of the key highlights of the quarter was Thyrocare’s rapidly expanding franchise network. Quarterly active franchisees reached an all-time high of nearly 10,800, up 15 percent year-on-year from 9,413 in Q4 FY25. The company served approximately 5.1 million patients during the quarter, reflecting 21 percent growth, while the average number of tests per patient increased to 10.9 from 10.2 last year. The franchise-led model continues strengthening Thyrocare’s omnichannel D2C strategy and nationwide healthcare accessibility.
The pathology business remained the key growth driver, with franchise revenue rising 21 percent year-on-year and partnership revenue increasing 23 percent. The franchise channel contributed 61 percent of pathology revenues, while partnership channels—including online diagnostic aggregators, healthcare platforms, employee wellness platforms, and institutional partnerships—contributed 34 percent. The direct-to-consumer segment contributed the remaining 5 percent, further strengthening Thyrocare’s direct consumer engagement strategy.
Thyrocare also continued expanding into advanced diagnostics and precision healthcare. During the quarter, the company launched advanced allergy testing solutions covering over 250 SKUs and entered the genomics segment through non-invasive pre-natal testing (NIPT). These developments position the company strongly within India’s growing precision diagnostics and personalised healthcare market.
The company expanded its lab network to 40 labs across India along with one international laboratory in Tanzania. In FY26, Thyrocare added new laboratories in Bhagalpur, Gwalior, Mandi, Davangere, Roorkee, and Vijayawada, strengthening geographic coverage and processing capacity across regions.
While the pathology segment continued driving strong growth, the company strategically rationalised its radiology business under Nuclear Healthcare Limited (NHL) by exiting non-profitable centres. Despite lower revenue in the radiology segment, profitability improved significantly, highlighting Thyrocare’s focus on sustainable operational growth and long-term efficiency.
As part of the daily digest of D2C news in India, Thyrocare’s Q4 FY26 performance highlights what’s happening in India’s D2C space today—where healthcare technology, diagnostics innovation, omnichannel expansion, preventive wellness, and scalable franchise-led business models are driving the next phase of growth across India’s healthcare ecosystem.
With strong profitability, expanding diagnostics capabilities, rising patient volumes, and growing healthcare infrastructure, Thyrocare continues strengthening its position as one of India’s leading diagnostics and preventive healthcare platforms while contributing to the broader evolution of India’s D2C business India and healthcare technology landscape.
